

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**CanSino Biologics Inc.**  
**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code: 6185)**

**VOLUNTARY ANNOUNCEMENT  
RECOMBINANT COVID-19 VACCINE  
(ADENOVIRUS TYPE 5 VECTOR) AND  
RECOMBINANT COVID-19 VACCINE  
(ADENOVIRUS TYPE 5 VECTOR) FOR INHALATION  
RECOMMENDED AS THE SECOND BOOSTER DOSE**

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

The Company is pleased to announce that, the Joint Prevention and Control Mechanism of the State Council in Response to the Novel Coronavirus Pneumonia (國務院應對新型冠狀病毒肺炎疫情聯防聯控機制綜合組) has issued the “Notice on the Implementation Plan for Vaccination of Second Booster Dose of COVID-19 Vaccines (新冠病毒疫苗第二劑次加強免疫接種實施方案的通知)”. The target population of the plan are: at the current stage and on the basis that the first booster dose has been vaccinated, the vaccination of the second booster dose can be launched in people with high risk of infection, elderly people over 60 years old, people with more serious chronic diseases and immunocompromised population. The interval is: according to the domestic and overseas real-world research and clinical trial data, and taking into account the actual vaccination status in China, the interval between the second booster dose and the first booster dose is at least 6 months.

Vaccine options are: priority shall be given to heterologous booster vaccination, or a second-dose booster with a vaccine containing or with good cross-immunogenicity to the Omicron variant. Our vaccines are involved as follows: 3 doses of inactivated vaccine + 1 dose of Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) (trade name: Convidecia®); 3 doses of inactivated vaccine + 1 dose of Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for inhalation (trade name: Convidecia Air™); or 2 doses of Convidecia® + 1 dose of Convidecia Air™.

After the Company’s Convidecia® and Convidecia Air™ are recommended as the second booster dose for vaccination, further purchases by relevant national authorities, if any, will have certain positive effects on the results of the Company.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, December 14, 2022

*As of the date of this announcement, the Board comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive Directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.*